Header image

Transforming Global Genetic Data into Medical Decisions

Our goal is the rapid medical diagnosis of inherited diseases, provided at the earliest possible moment as we turn analytical information into actionable results for physicians, patients and pharmaceutical partners.

Our commitment to the global medical community is an early and precise diagnosis for continuous improvement of therapeutic options for each individual patient.

Latest Scientific News

A homozygous frameshift variant in an alternatively spliced exon of DLG5…

Based on the ambition to provide maximum diagnostic yield, CENTOGENE offers follow up of…

Assessment of Cardiac Involvement in Fabry Disease (FD) with Native T1…

Mass-spectrometry based quantification of biomarkers is a routine step in the diagnostic…

Prodromal substantia nigra sonography undermines suggested association…

Parkinson’s disease (PD) and Gaucher disease are amongst the primary research foci at…

Utility and implications of exome sequencing in early-onset Parkinson's…

Although the genetic load is high in early-onset Parkinson’s disease, thorough…

Customer Feedback

Give feedback

Newsletter subscription

Agreement focused on identification of patients with Duchenne muscular dystrophy (DMD)

Read more

CENTOGENE, a rare disease company committed to improving the lives of rare disease patients by providing solutions that accelerate the development of drugs, has...

Read more

Driving Pharmaceutical Partnerships and Accelerating Orphan Drug Development

Read more

CENTOGENE’s state-of-the-art genetic laboratory facilities in Rostock, Germany awarded accreditation for the fourth year

Read more

2018 highlights include expansion to U.S., new partnerships with leading pharmaceutical companies, and growth of diagnostic testing portfolio for rare diseases...

Read more

NORTHFIELD, IL. — The College of American Pathologists (CAP), a Center for Medicare and Medicaid Services (CMS)-approved accreditation authority, has awarded...

Read more

Provides physicians with virtual encyclopedia of genetic information at their fingertips for improved and efficient diagnosis of rare diseases

Read more

CENTOGENE and Denali Therapeutics (NASDAQ: DNLI) today announced a strategic collaboration for the global identification and recruitment of LRRK2 mutation...

Read more

Joint drug discovery projects combine CENTOGENE’s patient access and biomarker expertise with Evotec's leading IPSC platform

Read more